The evidence from the AREDS2 trial indicates that while lutein and zeaxanthin are tested for AMD risk reduction, they did not show significant effects on progression to advanced AMD. The findings suggest a moderate level of support but highlight the need for comprehensive formulas for effective outcomes.
AMD progression to advanced AMD — primary RCT resultsAdults aged 50–85 at risk for advanced AMD (n=4,203) · Randomized clinical trial (AREDS2)Moderate
The AREDS2 primary report found lutein 10 mg + zeaxanthin 2 mg did not significantly reduce progression to advanced AMD vs placebo overall; however, secondary analyses showed lutein/zeaxanthin reduced risk in participants with the lowest dietary intake of these carotenoids. Long-term 10-year follow-up (AREDS2 Report 28) found HR 0.91 (95% CI 0.84–0.99) favoring lutein/zeaxanthin.
AMD progression risk modification (AREDS2 context)Adults at risk for advanced AMD · Large randomized clinical trial programModerate
NEI summaries describe AREDS2 testing lutein/zeaxanthin additions & related outcomes in AMD risk contexts.
Forms & usage▾
Take 10 mg of lutein and 2 mg of zeaxanthin daily, ideally with a meal.